Wondering whether Baxter International at US$20.86 is a bargain or a value trap? This article breaks down what the current share price might be telling you about the stock.
The stock has risen 7.6% over the past week and 20.6% over the past month, yet is still down 7.0% year to date and has declined 31.3% over the last year. This raises questions about how the market now views its risk and potential.
Recent coverage has focused on Baxter International’s position within the medical equipment space and how investors are reassessing companies in the sector, especially those with longer term share price declines such as the 51.1% fall over three years and 71.4% over five years. This context helps explain why some investors see recent short term gains as a possible sentiment shift rather than a firmly established trend.
Baxter International currently has a valuation score of 5/6. This sets the stage for comparing what different valuation methods suggest about the stock today and, later in the article, a more intuitive way to pull all these signals together.
Approach 1: Baxter International Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model takes estimated future cash flows, then discounts them back to what they might be worth in today’s dollars. It is a way of asking what Baxter International’s future cash generation could reasonably be worth right now.
Baxter International is currently generating last twelve month Free Cash Flow of about $751.4 million. Using a 2 Stage Free Cash Flow to Equity model, analyst projections and extrapolated estimates point to Free Cash Flow of $899 million in 2028, with a series of annual projections running out to 2035. Simply Wall St uses analyst estimates out to 2028 and then extends the trend to arrive at these later year figures.
Pulling these cash flows together, the model arrives at an estimated intrinsic value of $28.02 per share. Compared to the current share price of $20.86, this indicates the stock is trading at a 25.6% discount to the DCF estimate, based on this cash flow view alone.
For companies where earnings can be affected by one off items, the P/S ratio is often a useful cross check because it compares the stock price to revenue, which is usually more stable than profit in any given year.
In general, higher growth expectations and lower perceived risk tend to justify a higher sales multiple, while slower growth or higher uncertainty usually point to a lower, more conservative range.
Baxter International currently trades on a P/S ratio of 0.95x. This sits well below the Medical Equipment industry average of 2.65x and also below the peer group average of 4.44x. On these simple comparisons, the stock screens as relatively lowly priced against revenue.
Simply Wall St’s Fair Ratio for Baxter International is 1.17x. This is a proprietary estimate of what the P/S ratio might be based on factors such as the company’s earnings growth profile, industry, profit margins, market cap and risk characteristics. Because it blends these company specific drivers rather than relying only on broad peer or industry averages, it can provide a more tailored reference point.
Comparing the Fair Ratio of 1.17x with the current 0.95x P/S indicates that the stock is trading below this tailored benchmark.
Upgrade Your Decision Making: Choose your Baxter International Narrative
Earlier it was mentioned that there is an even better way to think about valuation, and that is where Narratives come in, letting you attach a clear story about Baxter International to the numbers you care about, such as your own view of fair value and estimates for future revenue, earnings and margins.
A Narrative links Baxter International’s business story to a financial forecast and then to a fair value, and on Simply Wall St’s Community page, which is used by millions of investors, you can see these Narratives laid out in an accessible format.
This helps you decide what action, if any, makes sense by comparing each Narrative’s fair value with the current share price, so you can see at a glance whether a particular story views Baxter International as priced above or below that estimate.
Because Narratives are updated when new information like news, guidance or earnings is added, the view does not stay static. You can compare, for example, a more cautious Baxter International Narrative that anchors around a US$17 fair value with a more optimistic one that points toward US$40, then decide which set of assumptions feels closer to how you see the company today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
